Efgartigimod Alfa Side Effects
Medically reviewed by Drugs.com. Last updated on Jan 12, 2024.
Applies to efgartigimod alfa: intravenous solution.
Serious side effects of efgartigimod alfa
Along with its needed effects, efgartigimod alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking efgartigimod alfa:
More common side effects
- bladder pain
- bloody or cloudy urine
- cough
- difficult, burning, or painful urination
- difficulty in moving
- fever
- frequent urge to urinate
- joint pain
- lower back or side pain
- muscle aches, cramps, pain, or stiffness
- sneezing
- sore throat
- swollen joints
Incidence not known
- difficulty in breathing or swallowing
- fast heartbeat
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- skin itching, rash, or redness
- swelling of the face, throat, or tongue
- trouble breathing
Other side effects of efgartigimod alfa
Some side effects of efgartigimod alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- headache
For healthcare professionals
Applies to efgartigimod alfa: intravenous solution.
General adverse events
The most common adverse reactions reported have included respiratory tract infections, headaches, and urinary tract infections.[Ref]
Respiratory
- Very common (10% or more): Respiratory tract infections (33%)
In clinical trials, 33% of patients treated with this drug experienced respiratory tract infections compared to 29% of placebo patients.
Nervous system
- Very common (10% or more): Headache (32%; included migraine, procedural headache)
- Common (1% to 10%): Paraesthesia (included oral hypoesthesia, hypoesthesia, hyperesthesia)
Immunologic
- Very common (10% or more): Drug antibodies (20%)
- Common (1% to 10%): Neutralizing antibodies
Hematologic
- Very common (10% or more): Below normal WBC counts (12%), below normal lymphocytes (28%), and below normal neutrophils (13%)
Below normal levels of WBCs, lymphocytes, and neutrophils were observed in patients treated with this drug (12%, 28%, and 13%, respectively) compared with placebo (5%, 19%, and 6%, respectively).
Genitourinary
- Very common (10% or more): Urinary tract infections (UTI; 10%)
In clinical trials, 10% of patients treated with this drug experienced UTI compared to 5% of placebo patients.
Hypersensitivity
- Frequency not reported: Hypersensitivity reactions including rash, angioedema, and dyspnea
Musculoskeletal
- Common (1% to 10%): Myalgia
References
1. (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.
More about efgartigimod alfa
- Check interactions
- Compare alternatives
- Reviews (12)
- Dosage information
- During pregnancy
- Drug class: immune globulins
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Efgartigimod alfa side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.